secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047402
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie appoints Thomas Falk (ex-Kimberly-Clark CEO) to board; Gonzalez, Tilton to retire July 1
--------------------------------------------------------------------------------

- Board expanded to 15; Thomas J. Falk (former Kimberly-Clark CEO) appointed as Class III director and to Audit Committee; deemed independent.
- Board to shrink to 13 upon retirement of Richard A. Gonzalez and Glenn F. Tilton effective July 1, 2025.
- Compensation Committee raised Robert A. Michael's 2025 annual bonus target to 165% of base salary for Chairman role.
- Shareholders ratified EY as auditor and approved say-on-pay; both management and stockholder proposals to eliminate supermajority voting failed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/tm2513856d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer